Bull Case

Life science demand and lab leasing reaccelerate as funding and occupancy improve, lifting same-store NOI and outperforming diversified REIT peers with slower growth.

Development deliveries and lease-up progress convert pipeline into cash flow, expanding FFO growth versus peers that rely more heavily on acquisitions or slower organic rent growth.

Lower rates and tighter credit spreads reduce financing pressure, improving interest coverage and supporting accretive capital deployment relative to highly levered office and retail landlords.

Embedded rent escalators and long lease durations sustain revenue visibility, allowing ARE to compound cash flow more steadily than shorter-duration property models.

Base Case

Core demand remains resilient but uneven, so occupancy and rent growth support modest NOI expansion while peers with weaker tenant bases face more volatility.

Development and redevelopment continue to add incremental earnings, but slower lease-up and higher capital costs temper FFO growth versus the strongest industrial and data-center peers.

High leverage and elevated interest expense keep earnings growth constrained, yet long-duration leases and recurring tenant demand prevent a sharper deterioration in operating results.

Valuation stays supported by quality assets and specialized tenant relationships, but the premium multiple remains capped by weaker coverage metrics than lower-leverage peers.

Bear Case

Biotech funding weakness and slower lab demand reduce absorption, pressuring occupancy and rent growth more than in broader healthcare or industrial REIT peers.

Refinancing at higher rates and persistent leverage strain cash flow, worsening interest coverage and limiting flexibility versus better-capitalized competitors.

Development delays or lease-up slippage defer NOI contribution, causing FFO growth to lag peers that are already harvesting completed projects.

If capital markets remain tight, asset sales or equity issuance become more dilutive, increasing balance-sheet risk and compressing per-share returns.

Overall Score

ARE’s forward profile remains strong because specialized life-science demand and development optionality support growth, while leverage and financing costs cap upside versus top peers.